Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 4/20 | 0.31 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828488 | 1.00 | MAPT (0.35) | MAPTMMP12MMP2MMP3CAPN1 | |
| SCHEMBL10773343 | 0.90 | MAPT (0.33) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL9300094 | 0.89 | KCNA5 (0.37) | MAPT | |
| SCHEMBL10434071 | 0.88 | PTPRC (0.34) | MAPT | |
| SCHEMBL10694453 | 0.88 | PTPRC (0.34) | MAPT | |
| SCHEMBL9730290 | 0.87 | TSHR (0.38) | MAPTCYP3A4 | |
| SCHEMBL30895707 | 0.85 | MEN1 (0.36) | MAPTSMN1; SMN2 | |
| SCHEMBL10433826 | 0.84 | MAPT (0.36) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL10562143 | 0.84 | MAPT (0.36) | MAPTMMP12MMP2MMP3GABBR2 | |
| SCHEMBL2910191 | 0.84 | MAPT (0.36) | MAPTMMP12MMP2MMP3GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4677211-A | Preparation of lactones | SANDOZ PHARMACEUTICALS CORP. (US) | 1987-06-30 | — | — | US | claimed |
| EP-0367895-A1 | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| WO-1990003973-A1 | PYRIMIDINYL-SUBSTITUTED HYDROXYACIDS, LACTONES AND ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1990-04-19 | — | — | WO | disclosed |
| EP-0327500-A2 | 5-Substituted 1H-pyrazolo[3,4-b]pyridine derivatives, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1989-08-09 | — | — | EP | disclosed |
| US-4822799-A | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals | SANDOZ PHARM. CORP. (US) | 1989-04-18 | — | — | US | disclosed |
| US-4808607-A | ATHEROSCLEROSIS, HYPERLIPOPROTEINEMIA | SANDOZ PHARM. CORP. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0244364-A2 | Preparation of olefinic compounds | SANDOZ AG (CH) | 1987-11-04 | — | — | EP | disclosed |
| US-4677211-A | Preparation of lactones | SANDOZ PHARMACEUTICALS CORP. (US) | 1987-06-30 | — | — | US | disclosed |